THE 60-SECOND GUIDE
KPV
Animal research.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
KPV is a three-amino-acid fragment associated with the alpha-MSH signaling family. Researchers study its effects on inflammation, especially in intestinal models. Its small size and biological rationale do not establish that it treats inflammatory disease in people. [1]
Potential benefits
Shows anti-inflammatory activity in laboratory and animal models. Derived from the melanocortin peptide alpha-MSH. [1]
Evidence & its limits
The cited work used cells and mice, not a clinical treatment trial. Reduced inflammatory signaling in those models does not establish patient benefit. Human efficacy and safety remain unresolved, including whether a commercial preparation reproduces the experimental material. [1]
Risks & unknowns
Human efficacy and safety are not established. Commercial claims often leap beyond preclinical evidence. [1]
Status & scope
The cited evidence is preclinical. Animal and cell studies cannot establish a clinical treatment benefit or human safety. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA KPV safety information
- PepT1-mediated KPV uptake: cell and mouse experiments, 2008
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.